Dalia Elganainy
0000-0003-4427-986X
16 papers found
Refreshing results…
Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity
Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma
Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden
Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy
Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies
Vasculature-Driven Biomechanical Deformable Image Registration of Longitudinal Liver Cholangiocarcinoma Computed Tomographic Scans
Accuracy of deformable image registration techniques for alignment of longitudinal cholangiocarcinoma CT images
Enhancement pattern mapping technique for improving contrast‐to‐noise ratios and detectability of hepatobiliary tumors on multiphase computed tomography
Computed Tomography–Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma
Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma.
Missing publications? Search for publications with a matching author name.